The Filing Desk

Travere Therapeutics

TVTX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

TVTX · Last close · November 13, 2026
$50.65
Value Travere Therapeutics yourself

Travere Therapeutics' revenue rose 110.5% to $491 million in fiscal 2025. Its operating margin was −12.8%, up from −138.9% a year earlier. The diluted share count rose 13.1%.

TRAVERE THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 19, 2026 · 0001438533-26-000014 Updated
Revenue
$491M
110.5%
Operating margin
−12.8%
126.1 pts
Net income
−$26M
 
Free cash flow
—
 
Return on equity
−29.4%
218.1 pts
Market cap
$4.8B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Travere Therapeutics does

Travere Therapeutics is a drug company based in San Diego that develops and sells medicines for rare kidney and metabolic diseases. Its main product is FILSPARI (sparsentan), which the U.S. Food and Drug Administration fully approved in September 2024 to slow the decline of kidney function in adults with primary IgA nephropathy, a rare, progressive kidney disease, who are at risk of getting worse. It had first won accelerated approval in February 2023. It also sells Thiola and Thiola EC, which treat cystinuria, a rare genetic disorder that causes recurring kidney stones.

It earns money by selling its approved medicines. As of the annual report, it was also seeking approval of FILSPARI for focal segmental glomerulosclerosis (FSGS), another rare kidney disease. It had asked the FDA for traditional approval, and the FDA's target date for a decision was extended to April 13, 2026.

It is also running a pivotal Phase 3 trial of pegtibatinase, an investigational enzyme replacement therapy for homocystinuria (HCU), a genetic disorder. It paused enrollment in September 2024 to improve the manufacturing process, and restarted it in the first quarter of 2026.

Its biggest risks, as it describes them

  • Its future depends heavily on selling FILSPARI well and winning acceptance from doctors, patients and payers.
  • Its late-stage programs may not win approval, including the FSGS application and pegtibatinase.
  • It faces generic and other competition, and its medicines must prove advantages over other therapies.
  • It depends on third parties to make and distribute its products.
  • Healthcare reform, price controls and changes in insurance reimbursement could cut pricing and demand.
From Travere Therapeutics's annual report on Form 10-K, filed February 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Travere Therapeutics lost money in fiscal 2025: a net loss of $26 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments428347307—238
Debt incl. finance leases227376377379312
Net debt (negative means net cash)−2012870—73
Net debt to EBITDA—————
Debt to equity0.8x8.8x1.9x6.4x2.7x
Interest coverage−10.1x−29.1x−34.4x−29.0x−5.8x
Current ratio4.7x3.4x3.5x2.1x2.7x
Quick ratio4.6x3.4x3.4x1.9x2.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Travere Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Travere Therapeutics shares on the open market, and 11 insiders sold $95.9 million, $94.5 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 17, 2026Eric M DubeChief Executive Officer, DirectorSold plan108,493$64.61$7.0 millionForm 4
Sep 17, 2026Peter HeermaEVP, Chief Commercial OfficerSold plan8,282$65.07$538,910Form 4
Sep 16, 2026Eric M DubeChief Executive Officer, DirectorSold plan195,841$63.45$12.4 millionForm 4
Sep 16, 2026Peter HeermaEVP, Chief Commercial OfficerSold plan172,717$63.43$11.0 millionForm 4
Sep 16, 2026William E. RoteChief Research OfficerSold plan112,850$63.33$7.1 millionForm 4
Sep 15, 2026Peter HeermaEVP, Chief Commercial OfficerSold plan102,190$62.26$6.4 millionForm 4
Sep 15, 2026William E. RoteChief Research OfficerSold plan96,198$62.25$6.0 millionForm 4
Sep 15, 2026Eric M DubeChief Executive Officer, DirectorSold plan95,666$62.25$6.0 millionForm 4
Sep 15, 2026Christopher R. ClineChief Financial OfficerSold plan50,508$62.34$3.1 millionForm 4
Sep 15, 2026Jula InrigEVP, Head of R&D & CMOSold plan44,674$62.34$2.8 millionForm 4
Sep 15, 2026Elizabeth E ReedChief Legal Officer and GCSold plan37,500$62.34$2.3 millionForm 4
Sep 15, 2026Sandra CalvinSVP, Chief Accounting OfficerSold plan5,375$62.33$335,026Form 4
The latest 12 of 69 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 93 of 97 of 9
Rule of 40−160.6%——
Altman Z''−3.95−9.10−5.38
Accruals ratio23.1%−12.2%−10.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassFailPass
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score4 of 93 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Travere Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Travere TherapeuticsFY25110.5%−12.8%———7
Mirum PharmaceuticalsFY2554.7%−4.2%10.5%−7.1%−34.9x5Compare
InnovivaFY2514.7%39.8%47.6%17.9%—6Compare
ArdelyxFY2522.1%−10.1%−10.8%−36.1%—2Compare
OPKO HealthFY25−14.9%−19.4%−31.4%−7.0%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue134155164175198132110145233491
Revenue growth33.7%16.0%6.0%6.8%13.1%−33.5%−17.0%32.7%60.5%110.5%
Gross profit129151159170192128105134225480
Research and development71781241411322018245218206
Operating income−58−54−80−137−176−199−320−388−324−63
Net income−48−60−103−146−169−180−278−111−322−26
Diluted EPS (US$)−1.29−1.54−2.54−3.46−3.56−3.01−4.37−1.50−4.08−0.29
Diluted shares (millions)38394042486064747989
Cash flow
Cash from operations−37−25−58−43−15−186−280−23838
Capital expenditure11107501——
Free cash flow−57−26−58−50−20−186−281——
Dividends paid0000000000
Share buybacks0000000000
Acquisitions10009500000
Stock-based compensation29272021243038443745
Balance sheet at fiscal year end
Cash and short-term investments41223311272357428347307—238
Debt incl. finance leases4445218205215227376377379312
Total assets525520709605607777673789594605
Total liabilities218227391384396474630588535490
Shareholders' equity3082933182212113024320159115
Margins and ratios
Gross margin96.6%97.7%96.6%97.0%96.9%97.1%96.0%92.1%96.7%97.9%
Operating margin−43.6%−34.7%−48.7%−78.3%−88.8%−151.3%−292.2%−267.2%−138.9%−12.8%
Net margin−35.9%−38.5%−62.5%−83.5%−85.4%−136.6%−254.4%−76.7%−137.9%−5.2%
Free cash flow margin−3.6%4.2%−15.6%−33.3%−25.0%−15.1%−170.4%−193.3%——
Rule of 40 (growth + FCF margin)30.1%20.2%−9.6%−26.6%−11.9%−48.6%−187.3%−160.6%——
Return on capital−14.9%−19.9%−37.2%−57.3%−124.2%−184.6%−293.9%−179.1%——
Return on equity−15.8%−19.9%−33.6%−54.3%−78.4%−70.2%−161.5%−91.4%−247.4%−29.4%
Return on assets−9.2%−11.4%−16.7%−22.3%−27.9%−26.0%−38.4%−15.2%−46.5%−4.3%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Travere Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Travere Therapeutics.